United States· US:72065-140_0b8d0863-8a2a-4a46-9f96-a759f3858bed
Gvoke Kit
A glucagon product containing glucagon injection, solution, registered in United States by Xeris Pharmaceuticals, Inc.. The same ATC class is registered in 17 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Glucagon is registered in 17 of 19 countries.
Countries holding a registration under ATC H04AA01 (glucagon), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 9 of them publish a price we can compare per daily dose
Glucagon · ATC H04AA01
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of glucagon costs, country by country.
Normalised to the WHO defined daily dose (3 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Glucagon · price per daily dose (3 mg)
USD · FX 28 Sept 2026
- CH Switzerland$104.78
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- glucagon injection, solution
- Manufacturer
- Xeris Pharmaceuticals, Inc.
- Country
- United States (US)
- ATC code
- H04AA01
- ATC class
- Glucagon
- Defined daily dose
- 3 mg, N
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 12, 2026
Packs & prices · 1
- ndc117206514011.2 mL in 1 CARTON (72065-140-11)
Regulatory notes
Interactions
22 interactions on record for glucagon.
Graded by severity as the source publishes them — 1 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Glucagon · interactions on record
22 records
- 1 moderate
- 21 minor
Most severe, free to view
- IndometacinM01AB01moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Glucagon in 17 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsBaqsimi 3 mg, snuifpoederAmphastar France Pharmaceuticals
- FinlandBaqsimiOrifarm Oy
- IrelandBaqsimi 3 mg nasal powder in single-dose containerAmphastar France Pharmaceuticals, S.A.S.
- United KingdomGlucaGen Hypokit 1mg powder and solvent for solution for injectionImported
- PolandBaqsimiAmphastar France Pharmaceuticals
- BelgiumBaqsimi 3 mgAmphastar France Pharmaceuticals
- NorwayBaqsimiAmphastar France Pharmaceuticals
- GermanyGlucagenNovo Nordisk Pharma Gmbh
Authorised across Europe · EMA
The same active substance is authorised in 30 EEA countries. Names it is sold under:
- Austria · Glucagen, Glucagen Hypokit
- Belgium · Glucagen, Glucagen Hypokit
- Bulgaria · Глюкаген Хипокит
- Cyprus · Glucagen Hypokit
- Czechia · Glucagen Hypokit
- Germany · Glucagen, Glucagen Hypokit
- Denmark · Glucagen, Glucagen Hypokit
- Estonia · Glucagen Hypokit
- Spain · Glucagen Hypokit
- Finland · Glucagen
- France · Glucagen, Glucagen Kit
- Greece · Glucagen, Glucagen Hypokit
- Croatia · Glucagen Hypokit
- Hungary · Glucagen Hypokit
- Ireland · Glucagen Hypokit
- Iceland · Baqsimi, Glucagen
- Italy · Glucagen, Glucagen Hypokit
- Liechtenstein · Baqsimi
- Lithuania · Glucagen Hypokit
- Luxembourg · Glucagen, Glucagen Hypokit
- Latvia · Glucagen Hypokit
- Malta · Glucagen, Glucagen Hypokit
- Netherlands · Glucagen, Hypokit
- Norway · Baqsimi, Glucagon
- Poland · Glucagen Hypokit
- Portugal · Glucagen, Glucagen Hypokit
- Romania · Glucagen Hypokit
- Sweden · Glucagon Novo Nordisk
- Slovenia · Glucagen Hypokit
- Slovakia · Glucagen Hypokit
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fe99aabe-d469-4398-b346-2b2c769febda GET /v1/drugs/fe99aabe-d469-4398-b346-2b2c769febda?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unii": {
"unii": "76LA80IG2G",
"rxcui": "4832",
"inchikey": null,
"display_name": "GLUCAGON",
"substance_type": "protein",
"ingredient_type": "INGREDIENT SUBSTANCE"
},
"route": "SUBCUTANEOUS",
"livertox": {
"summary": null,
"livertox_id": null,
"hepatotoxicity_score": 5
},
"spl_meta": {
"92385737-dbad-98c5-e053-2995a90a2805": {
"match": "brand_token",
"title": "GVOKE HYPOPEN 1 MG AUTO-INJECTOR (GLUCAGON INJECTION, SOLUTION) INJECTION, SOLUTION GVOKE HYPOPEN 0.5 MG AUTO-INJECTOR (GLUCAGON INJECTION, SOLUTION) INJECTION, SOLUTION GVOKE PFS 1 MG PRE-FILLED SYRINGE (GLUCAGON INJECTION, SOLUTION) INJECTION, SOLUTION GVOKE PFS 0.5 MG PRE-FILLED SYRINGE (GLUCAGON INJECTION, SOLUTION) INJECTION, SOLUTION GVOKE KIT (GLUCAGON INJECTION, SOLUTION) INJECTION, SOLUTION [XERIS PHARMACEUTICALS, INC.]",
"spl_version": "20",
"published_date": "2026-01-23"
}
},
"productid": "72065-140_0b8d0863-8a2a-4a46-9f96-a759f3858bed",
"productndc": "72065-140",
"dosage_form": "INJECTION, SOLUTION",
"orange_book": {
"appl_no": "212097",
"products": [
{
"rs": false,
"rld": true,
"te_code": null,
"strength": "0.5MG/0.1ML (0.5MG/0.1ML)",
"product_no": "001",
"approval_date": "Sep 10, 2019"
},
{
"rs": true,
"rld": true,
"te_code": null,
"strength": "1MG/0.2ML (1MG/0.2ML)",
"product_no": "002",
"approval_date": "Sep 10, 2019"
},
{
"rs": true,
"rld": true,
"te_code": null,
"strength": "0.5MG/0.1ML (0.5MG/0.1ML)",
"product_no": "003",
"approval_date": "Sep 10, 2019"
},
{
"rs": true,
"rld": true,
"te_code": null,
"strength": "1MG/0.2ML (1MG/0.2ML)",
"product_no": "004",
"approval_date": "Sep 10, 2019"
},
{
"rs": true,
"rld": true,
"te_code": null,
"strength": "1MG/0.2ML (1MG/0.2ML)",
"product_no": "005",
"approval_date": "Aug 20, 2021"
},
{
"rs": true,
"rld": true,
"te_code": null,
"strength": "1MG/0.2ML (1MG/0.2ML)",
"product_no": "006",
"approval_date": "Mar 14, 2025"
}
],
"appl_type": "N"
},
"dea_schedule": null,
"product_type": "HUMAN PRESCRIPTION DRUG",
"substance_name": "GLUCAGON",
"proprietary_name": "Gvoke Kit",
"active_ingred_unit": "mg/.2mL",
"application_number": "NDA212097",
"marketing_category": "NDA",
"nonproprietary_name": "glucagon injection, solution",
"start_marketing_date": "20211011",
"active_numerator_strength": "1"
}See everything about glucagon.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.